-
多囊卵巢综合征(polycystic ovary syndrome, PCOS)是以雄激素增多和胰岛素抵抗为特征的一组内分泌疾病。大部分PCOS患者增多的雄激素主要来源于卵巢, 但仍有20%~30%的患者主要来源于肾上腺[1]。高胰岛素血症可直接或间接引起PCOS患者卵巢源性的雄激素水平增加, 但是否会引起肾上腺源性的雄激素增多, 以及胰岛素抵抗与肾上腺源性雄激素增多是否相关尚不明确。本研究采用对比促肾上腺皮质激素(adrenocorticotropic hormone, ACTH)兴奋试验前后17-羟孕酮(17-hydroxyprogesterone, 17-OHP)、硫酸脱氢表雄酮(dehydroepiandrosteronesulfate, DHEAS)和雄烯二酮(androstenedione, AD)的变化与稳态模型下胰岛素抵抗指数(homeostasis modes of assessment for insulin resistence index, HOMA-IR)的关系, 探讨PCOS患者肾上腺源性雄激素增多与胰岛素抵抗的关系。
-
85例PCOS患者经ACTH兴奋试验后, 有20例17-OHP水平高于正常, 为HR-PCOS组, 其余65例反应正常, 为NR-PCOS组。
ACTH兴奋试验前PCOS患者临床特征和激素水平见表 1。HR-PCOS组和NR-PCOS组的BMI及腰臀围比显著高于对照组(BMI: χ2=13.874, 14.512, 腰臀围比: χ2=12.607, 15.153, P均 < 0.05), HR-PCOS组和NR-PCOS组间差异无统计学意义(χ2=4.801, 5.326, P均 > 0.05);NR-PCOS组和HR-PCOS组的LH/FSH、雌二醇水平显著高于对照组(LH/FSH: χ2= 18.226, 16.327, 雌二醇: χ2=17.334, 19.261, P均 < 0.01), 而PCOS两组间差异无统计学意义(χ2= 4.028, 6.116, P均 > 0.05), HR-PCOS组总睾酮水平显著高于NR-PCOS组(χ2=12.274, P < 0.05), 并且两组均高于对照组(χ2=20.314, 18.492, P均 < 0.01);NRPCOS组和HR-PCOS组HOMA-IR均显著高于对照组(χ2=19.263, 21.482, P均 < 0.01), 且HR-PCOS组显著高于NR-PCOS组(χ2=13.582, P < 0.05)。
组别 例数 BMI(kg/m2) 腰臀围比 LH/FSH 雌二醇(ng/L) 孕酮(μg/L) 总睾酮(μg/L) HOMA-IR 正常对照组 22 18.31±3.10 0.19±0.08 1.22±0.40 21.93±8.52 0.21±0.07 0.65±0.42 0.71±0.39 NR-PCOS组 65 25.62±5.23 0.81±0.11 2.11±0.80 60.62±25.11 0.31±0.16 1.43±0.16 2.13±0.74 HR-PCOS组 20 24.41±4.81 0.87±0.06 2.31±0.71 59.31±20.42 0.39±0.18 1.75±0.32 3.52±0.48 注:表中,NR-PCOS为促肾上腺皮质激素兴奋试验正常反应的多囊卵巢综合征;HR-PCOS为促肾上腺皮质激素兴奋试验高反应的多囊卵巢综合征;BMI为体质量指数;LH/FSH为促黄体生成素与卵泡刺激素水平比值;HOMA-IR为稳态模型下胰岛素抵抗指数。 表 1 多囊卵巢综合征患者临床特征、激素水平(x±s)
ACTH兴奋试验对PCOS患者激素水平的影响见表 2。由表 2可见, ACTH兴奋试验前后HRPCOS组17-OHP和DHEAS水平显著高于NRPCOS组和对照组(17-OHP: χ2=18.063, 19.214, DHEAS: χ2=17.358, 19.355, P均 < 0.01), 而NR-PCOS组与对照组间差异无统计学意义(χ2=4.109, 4.362, P均 > 0.05), AD水平在ACTH兴奋试验前后HRPCOS组和NR-PCOS组均高于对照组(χ2=14.062, 16.549, P均 < 0.05), 而HR-PCOS组与NR-PCOS组间差异无统计学意义(χ2=5.541, P > 0.05)。皮质醇水平在兴奋试验前后各组间差异无统计学意义。
组别 例数 17-OHP(μg/L) DHEASO(nmol/L) AD(μg/L) 皮质醇(nmol/L) 兴奋试验前 兴奋试验后 兴奋试验前 兴奋试验后 兴奋试验前 兴奋试验后 兴奋试验前 兴奋试验后 正常对照组 22 1.20±0.25 3.72±0.75 248.3±84.50 250.5±86.41 1.63±0.54 2.81±0.71 21.06±4.47 25.11±6.03 NR-PCOS组 65 1.18±0.16 3.65±0.80 356.7±187.20 396.8±202.70 2.06±0.75 3.16±0.42 18.25±7.10 23.44±5.81 HR-PCOS组 20 1.83±0.32 7.03±1.03 461.9±201.20 508.3±210.20 2.33±0.92 3.48±0.51 19.93±5.73 24.21±7, 17 注:表中,NR-PCOS为促肾上腺皮质激素兴奋试验正常反应的多囊卵巢综合征;HR-PCOS为促肾上腺皮质激素兴奋试验高反应的多囊卵巢综合征;17-OHP为17-羟孕酮;DHEAS为硫酸脱氢表雄酮;AD为雄烯二酮。 表 2 促肾上腺皮质激素兴奋试验前后多囊卵巢综合征患者雄激素水平(x±s)
多囊卵巢综合征患者肾上腺雄激素水平与胰岛素抵抗的关系
The relationship of adrenal androgen level and insulin resistance in polycystic ovary syndrome patients
-
摘要:
目的 探讨多囊卵巢综合征(PCOS)患者肾上腺源性雄激素水平与胰岛素抵抗的关系。 方法 对22名正常女性和85例PCOS患者行促肾上腺皮质激素(ACTH)兴奋试验,将PCOS患者分为高反应组(HR-PCOS)和正常反应组(NR-PCOS)。用放射免疫分析法检测血清促黄体生成素与卵泡刺激素(LH/FSH)比值、雌二醇、睾酮、孕酮,测定ACTH兴奋试验前后(0 min和60 min)血清17-羟孕酮(17-OHP)、硫酸脱氢表雄酮(DHEAS)、雄烯二酮(AD)、皮质醇,测定稳态模型下胰岛素抵抗指数(HOMA-IR),测量体质量指数(BMI)、腰臀围比。 结果 在85例PCOS患者中,有20例的17-OHP水平高于正常,为HR-PCOS组,其余65例反应正常,为NR-PCOS组。基本情况比较: HR-PCOS组和NR-PCOS组的MBI及腰臀围比均显著高于对照组(MBI:χ2=13.874,14.512, 腰臀围比:χ2=12.607, 15.153,P均 < 0.05),HR-PCOS组和NR-PCOS组间差异无统计学意义(χ2=4.801, 5.362,P > 0.05);激素水平比较:HR-PCOS组和NR-PCOS组的LH/FSH比值、雌二醇显著高于对照组(LH/FSH:χ2=18.226, 16.327, 雌二醇:χ2=17.334,19.261,P均 < 0.01),HR-PCOS组和NR-PCOS组间差异无统计学意义;HR-PCOS组血清总睾酮显著高于NR-PCOS组(χ2=12.274,P < 0.05),HR-PCOS组和NR-PCOS组均高于对照组(χ2=20.314,18.492,P均 < 0.01);ACTH兴奋试验前后HR-PCOS组17-OHP和DHEAS显著高于NR-PCOS组和对照组(17-OHP:χ2=18.063, 19.214, DHEAS:χ2=17.358, 19.355,P均 < 0.01),而NR-PCOS组与对照组间差异无统计学意义(χ2=4.109, 4.362,P均 > 0.05);AD在ACTH兴奋试验前后HR-PCOS组和NR-PCOS组均高于对照组(χ2=14.062,16.549,P均 < 0.05),而HR-PCOS组和NR-PCOS组间差异无统计学意义(χ2=5.541,P > 0.05);血清皮质醇在ACTH兴奋试验前后各组间差异无统计学意义;HR-PCOS组和NR-PCOS组的HOMA-IR均显著高于对照组(χ2=19.263,21.482,P均 < 0.01),且HR-PCOS组显著高于NR-PCOS组(χ2=13.582,P均 < 0.05)。 结论 部分PCOS患者存在肾上腺雄激素亢进并对ACTH反应性增强,其肾上腺雄激素的水平可能与胰岛素抵抗有关。 Abstract:Objective To investigate the relationship between adrenal androgen level and insulin resistance in polycystic ovary syndrome(PCOS)patients. Method Twenty-two healthy women and 85 PCOS patients were underwent adrenocorticptropic hormone(ACTH)stimulation test, and 85 PCOS patients were divided into high response-polycystic ovary syndrome(HR-PCOS)group and normal response-polycystic ovary syndrome(NR-PCOS)group.The ratio of serum luteinizing hormone to follicle stimulating hormone(LH/FSH), estradiol(E2), testosterone(T)and progestin(P)were tested by radioimmunoassay method.17-hydroxyprogesterone(17-OHP), dehydroepiandros-teronesulfate(DHEAS)and androsterone(AD)was tested at 0 and 60 min after an ACTH stimulation test.Body mass index(BMI), waist-to-hip-circumference radio(WHR)and homeostasis modes ofassessment for insulin resistence index(HOMA-IR)were also measured. Results There were 20 cases that 17-OHP levels were higher than normal(HR-PCOS), the other 65 cases were NR-PCOSgroup.MBI and WHR(MBI: χ2=13.874, 14.512, WHR: χ2=12.607, 15.153, P all < 0.05)of HR-PCOS group and NR-PCOS group were significantly higher than control group, but there had no significant difference between the two PCOS groups(χ2=4.801, 5.326, P all > 0.05).HR-PCOS group and NR-PCOS group were significantly higher than the control group for LH/FSH and estradiol(LH/FSH: χ2=18.226, 16.327, E2: χ2=17.334, 19.261, P all < 0.05), but there had no significant difference between the two PCOS groups.Serum T of HR-PCOS group was significantly higher than control group(χ2=12.274, P < 0.01), HR-PCOS group and NR-PCOS group were higher than control group(χ2=20.314, 18.492, P all < 0.01).17-OHP and DHEAS of HR-PCOS group were significantly higher than NR-PCOS group and control group before and after ACTH stimulation test(17-OHP: χ2=18.063, 19.214, DHEAS: χ2=17.358, 19.355, P all < 0.01).But there had no differences between NR-PCOS group and control group(χ2=4.109, 4.362, P all > 0.05).AD of HR-PCOS group and NR-PCOS group were higher than control group before and after the ACTH stimulation test(χ2=14.062, 16.549, P all < 0.05).However, there had no differences(χ2=5.541, P > 0.05)between the two PCOS groups.Serum cortisol was no difference between HR-PCOS, NR-PCOS and control groups before and after stimulation test.HOMA-IR of HR-PCOS group and NR-PCOS group were higher than control group(χ2=19.263, 21.482, P all < 0.01), and HR-PCOS group is higher than NR-PCOS group(χ2=13.582, P < 0.05). Conclusions There have significantly higher basal and ACTH-stimulated level of adrenal androgen hyperresponsiveness in PCOS patients.Adrenal androgen level appears to be closely associated with insulin resistance in PCOS patients. -
表 1 多囊卵巢综合征患者临床特征、激素水平(x±s)
组别 例数 BMI(kg/m2) 腰臀围比 LH/FSH 雌二醇(ng/L) 孕酮(μg/L) 总睾酮(μg/L) HOMA-IR 正常对照组 22 18.31±3.10 0.19±0.08 1.22±0.40 21.93±8.52 0.21±0.07 0.65±0.42 0.71±0.39 NR-PCOS组 65 25.62±5.23 0.81±0.11 2.11±0.80 60.62±25.11 0.31±0.16 1.43±0.16 2.13±0.74 HR-PCOS组 20 24.41±4.81 0.87±0.06 2.31±0.71 59.31±20.42 0.39±0.18 1.75±0.32 3.52±0.48 注:表中,NR-PCOS为促肾上腺皮质激素兴奋试验正常反应的多囊卵巢综合征;HR-PCOS为促肾上腺皮质激素兴奋试验高反应的多囊卵巢综合征;BMI为体质量指数;LH/FSH为促黄体生成素与卵泡刺激素水平比值;HOMA-IR为稳态模型下胰岛素抵抗指数。 表 2 促肾上腺皮质激素兴奋试验前后多囊卵巢综合征患者雄激素水平(x±s)
组别 例数 17-OHP(μg/L) DHEASO(nmol/L) AD(μg/L) 皮质醇(nmol/L) 兴奋试验前 兴奋试验后 兴奋试验前 兴奋试验后 兴奋试验前 兴奋试验后 兴奋试验前 兴奋试验后 正常对照组 22 1.20±0.25 3.72±0.75 248.3±84.50 250.5±86.41 1.63±0.54 2.81±0.71 21.06±4.47 25.11±6.03 NR-PCOS组 65 1.18±0.16 3.65±0.80 356.7±187.20 396.8±202.70 2.06±0.75 3.16±0.42 18.25±7.10 23.44±5.81 HR-PCOS组 20 1.83±0.32 7.03±1.03 461.9±201.20 508.3±210.20 2.33±0.92 3.48±0.51 19.93±5.73 24.21±7, 17 注:表中,NR-PCOS为促肾上腺皮质激素兴奋试验正常反应的多囊卵巢综合征;HR-PCOS为促肾上腺皮质激素兴奋试验高反应的多囊卵巢综合征;17-OHP为17-羟孕酮;DHEAS为硫酸脱氢表雄酮;AD为雄烯二酮。 -
[1] Kumar A, Woods KS, Bartulucci AA, et al. Prevalence of adrenal andmgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol(Oxf), 2005, 62(6): 644-649. doi: 10.1111/j.1365-2265.2005.02256.x [2] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Work-shop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystie ovary syndrome. Fertil Steril, 2004, 81(2): 19-25. [3] Yildiz BO, Azziz R. The adrenal and polycystic ovary syndrome. Rev Endocr Metab Disord, 2007, 8(4): 331-342. doi: 10.1007/s11154-007-9054-0 [4] Ehrmann DA. Polycystic ovary syndrome. N Engl J Med, 2005, 352(4): 1223-1236. [5] New MI, Lorensen F, lerner AJ, et al. Genotyping steroid 21-hy-droxylase deficiency: hormonal reference data. J Clin Endocrinol Metab, 1983, 57(2): 320-326. doi: 10.1210/jcem-57-2-320 [6] 韩晓芬, 钟雪梅. 多囊卵巢综合征胰岛素抵抗的研究进展. 西南军医, 2009, 11(1): 76-78. doi: 10.3969/j.issn.1672-7193.2009.01.042
[7] 陶弢, 刘伟, 杨洁谨, 等. 多囊卵巢综合征患者下丘脑-垂体-肾上腺轴改变与胰岛素抵抗的关系. 中华内分泌代谢杂志, 2010, 26(5): 368-369. doi: 10.3760/cma.j.issn.1000-6699.2010.05.006
[8] Vrbikova J, Hill M, Dvorakova K, et al. Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome. Gynecol Obstet Invest, 2004, 58(1): 36-41. doi: 10.1159/000077827 [9] Guido M, Romualdi D, Suriano R, et al. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Hum Reprod, 2004, 19(3): 534-539. doi: 10.1093/humrep/deh145